×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
KZIA – kazia therapeutics limited - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
KZIA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/30
09:07 am
kzia
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) [Yahoo! Finance]
Medium
Report
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) [Yahoo! Finance]
1/30
08:00 am
kzia
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
Medium
Report
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
1/28
08:41 am
kzia
Novogen (NASDAQ:KZIA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Medium
Report
Novogen (NASDAQ:KZIA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
1/27
08:00 am
kzia
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
High
Report
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
1/24
05:09 am
kzia
Novogen (NASDAQ:KZIA) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
Novogen (NASDAQ:KZIA) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
1/8
09:00 am
kzia
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
Low
Report
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
12/22
08:10 am
kzia
Kazia Therapeutics Regains Full Nasdaq Listing Compliance [Yahoo! Finance]
Medium
Report
Kazia Therapeutics Regains Full Nasdaq Listing Compliance [Yahoo! Finance]
12/22
08:00 am
kzia
Kazia Therapeutics Regains Full Nasdaq Listing Compliance
Medium
Report
Kazia Therapeutics Regains Full Nasdaq Listing Compliance
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/27
08:26 am
kzia
Form 424B3 KAZIA THERAPEUTICS LTD
High
Report
Form 424B3 KAZIA THERAPEUTICS LTD
1/27
08:24 am
kzia
Form 424B3 KAZIA THERAPEUTICS LTD
High
Report
Form 424B3 KAZIA THERAPEUTICS LTD
1/27
08:22 am
kzia
Form 424B3 KAZIA THERAPEUTICS LTD
High
Report
Form 424B3 KAZIA THERAPEUTICS LTD
1/27
08:20 am
kzia
Form 424B3 KAZIA THERAPEUTICS LTD
High
Report
Form 424B3 KAZIA THERAPEUTICS LTD
1/27
08:10 am
kzia
Form 6-K KAZIA THERAPEUTICS LTD For: Jan 27
High
Report
Form 6-K KAZIA THERAPEUTICS LTD For: Jan 27
1/23
04:00 pm
kzia
Form SCHEDULE 13G KAZIA THERAPEUTICS LTD Filed by: Lynwood Capital Management Inc.
Medium
Report
Form SCHEDULE 13G KAZIA THERAPEUTICS LTD Filed by: Lynwood Capital Management Inc.
12/29
06:03 am
kzia
Form EFFECT KAZIA THERAPEUTICS LTD
High
Report
Form EFFECT KAZIA THERAPEUTICS LTD
12/29
06:02 am
kzia
Form EFFECT KAZIA THERAPEUTICS LTD
High
Report
Form EFFECT KAZIA THERAPEUTICS LTD
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/8
New positive data from phase IIa trial in brain cancer patients
12.8%
4/29 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 8.0%
8/20 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 4.7%
2/10 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 3.2%
6/23 Edison issues ADR outlook on Kazia Therapeutics (KZIA) 3.1%
2/4 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 2.9%
1/7 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 2.1%
12/26 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 1.6%
4/4 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock. 1.5%
6/27 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock. 1.4%
4/29 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 8.0%
8/20 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 4.7%
2/10 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 3.2%
6/23 Edison issues ADR outlook on Kazia Therapeutics (KZIA) 3.1%
2/4 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 2.9%
1/7 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 2.1%
12/26 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 1.6%
4/4 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock. 1.5%
6/27 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock. 1.4%
TOP News Decliners
11/20
Kazia Therapeutics up 83% [Seeking Alpha]
-18.9%
11/19 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -8.6%
5/8 Kazia calls for greater awareness of the deadliest gynecological cancer in the US -8.5%
7/17 Kazia calls for greater awareness of the deadliest brain cancer in the US -8.4%
4/8 Kazia Therapeutics up 18% premarket on positive paxalisib data [Seeking Alpha] -8.0%
11/25 Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference -7.4%
12/2 Edison issues ADR outlook on Kazia Therapeutics (KZIA) -6.7%
12/14 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -6.0%
1/14 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -2.9%
1/24 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -2.4%
11/19 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -8.6%
5/8 Kazia calls for greater awareness of the deadliest gynecological cancer in the US -8.5%
7/17 Kazia calls for greater awareness of the deadliest brain cancer in the US -8.4%
4/8 Kazia Therapeutics up 18% premarket on positive paxalisib data [Seeking Alpha] -8.0%
11/25 Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference -7.4%
12/2 Edison issues ADR outlook on Kazia Therapeutics (KZIA) -6.7%
12/14 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -6.0%
1/14 Kazia Therapeutics Ltd (NASDAQ: KZIA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -2.9%
1/24 Kazia Therapeutics Ltd (NASDAQ: KZIA) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -2.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: